Powered vs. Manual Toothbrushing in Stage 3-4 Periodontitis
Launched by UNIVERSITY OF L'AQUILA · May 16, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This single-blind, randomized controlled trial evaluates the clinical effectiveness of powered versus manual toothbrushing in patients newly diagnosed with stage 3 or 4 periodontitis. Participants are randomly assigned to one of two groups: powered toothbrush (Oral-B iO6) or manual toothbrush (TePe Select Soft). All participants receive standardized oral hygiene instructions and are instructed to brush twice daily for a minimum of two minutes. Manual brush users are required to use a smartphone app to monitor and record brushing duration. The use of adjunctive oral hygiene aids, such as mou...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 to 75 years
- • Diagnosis of stage 3 or 4 periodontitis based on clinical and radiographic examination
- • Retaining at least 16 natural teeth
- • Ability to follow oral hygiene instructions and compliance with the study protocol
- • Willingness to refrain from using additional oral hygiene products (e.g., mouthwash, interdental cleaners) during the study
- • Ability to provide informed consent
- Exclusion Criteria:
- • Presence of systemic conditions that may affect oral health (e.g., uncontrolled diabetes, immunocompromised states)
- • Pregnancy or breastfeeding
- • Ongoing use of antibiotics or other medications that could interfere with gum health
- • Severe dental conditions (e.g., tooth mobility \> 2, advanced root resorption)
- • Prior use of a powered toothbrush within the last 6 months
- • Participation in another clinical trial that could interfere with study outcomes
- • Inability or unwillingness to comply with study requirements or provide informed consent
About University Of L'aquila
The University of L'Aquila, a prestigious academic institution in Italy, is committed to advancing medical research and innovation through rigorous clinical trials. With a strong focus on interdisciplinary collaboration, the university leverages its expertise in biomedical sciences to investigate new therapies and treatment strategies. The institution's dedication to ethical standards and patient safety ensures that all research initiatives are conducted with the highest level of scientific integrity. By fostering partnerships with healthcare professionals and industry stakeholders, the University of L'Aquila aims to contribute significantly to the global medical community and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
L'aquila, , Italy
Patients applied
Trial Officials
Davide Pietropaoli, DDS, PhD
Principal Investigator
University of L'Aquila
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported